Advice

following an abbreviated submission:

bevacizumab gamma (Lytenava®) is accepted for use within NHSScotland.

Indication under review: in adults for treatment of neovascular (wet) age-related macular degeneration (nAMD).

Bevacizumab gamma offers an additional treatment choice in the therapeutic class of vascular endothelial growth factor inhibitors.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Download detailed advice279KB (PDF)

Download

Medicine details

Medicine name:
bevacizumab gamma (Lytenava)
SMC ID:
SMC2744
Indication:

In adults for treatment of neovascular (wet) age-related macular degeneration (nAMD)

Pharmaceutical company
Outlook Therapeutics Ltd
BNF chapter
Eye
Submission type
Abbreviated
Status
Accepted
Date advice published
09 June 2025